Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial - ScienceDirect

https://www.sciencedirect.com/science/article/pii/S0140673621016949?casa_token=yVkbsRtmQOMAAAAA:pAUo31cErIOzBg6lfLAXM5gcmZ6MhpfMhvarp1VeYDoZkLWQMn6CjQYroAh3C14qDg6Iu_KdDw